Pharmacy Times
JUNE 4, 2024
The immunizing technicians stated they had greater job satisfaction and had a greater sense of being valuable pharmacy members
STAT
JUNE 6, 2024
The Covid pandemic has been called a “mass-disabling event” since early on — the kind of once-in-a-generation public health crisis that could shape millions of people’s lives forever. But while more people self-identified as disabled since the pandemic began, applications for disability benefits have stayed level, according to data from the Social Security Administration.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
JUNE 7, 2024
Once hailed as an anti-aging magic bullet, telomerase has failed to live up to the hype as it was profiled in a | The FDA has approved Geron Corporation's Rytelo (imetelstat) to treat a group of bone marrow disorders called myelodysplastic syndrome (MDS). The approval is the first for the 33-year-old California biotech.
Fierce Healthcare
JUNE 3, 2024
The nation’s largest nurses union is demanding that artificial intelligence tools used in healthcare be proven safe and equitable before deployment. | A union organization for nurses nationwide says the deployment of AI in healthcare will push nurses out of patient rooms and compromise patient safety. A new AI Bill of Rights lays out nurse and patient protections, which are not currently being met.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
JUNE 5, 2024
The investigators are optimistic that the data can establish stress-related pathways while revealing potential therapeutic options for patients with major depressive disorder and post-traumatic stress disorder.
STAT
JUNE 7, 2024
When large swaths of the East Coast were shrouded in wildfire smoke last summer, scientists in California grimly joked that maybe, finally, power brokers in New York and Washington, D.C. would be spurred to act on the burning issue that has long plagued the West Coast. Despite wildfire seasons that regularly burn hundreds of thousands of acres in California alone each year, researchers know relatively little about the long-term effects of chronic wildfire smoke on the body , and funding to reduc
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Healthcare
JUNE 7, 2024
Walmart announced that it is closing all 51 of its health centers and virtual care ope | The hope that retailers were poised to offer a scaled-up solution has yielded to a more realistic view that, at best, it will be a long journey.
Pharmacy Times
JUNE 6, 2024
By improving health insurance coverage and cost of inhalers, such as out-of-pocket caps, access to care can be increased. Some companies are aiming to improve access by implementing price caps.
STAT
JUNE 7, 2024
The Food and Drug Administration on Friday expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50. Arexvy, which was the first RSV vaccine approved , now becomes the first to be available to adults under the age of 60 who are not pregnant. Prior to this FDA decision, Arexvy was licensed for use in people 60 and older.
Fierce Pharma
JUNE 4, 2024
A little less than a year after Eli Lilly won the blessing of England's drug value watchdog for tirzepatide in Type 2 diabetes, the National Institute for Health and Care Excellence (NICE) has retu | A little less than a year after Eli Lilly won the blessing of England's drug value watchdog for tirzepatide in Type 2 diabetes, the National Institute for Health and Care Excellence (NICE) has returned with an endorsement in obesity.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
JUNE 3, 2024
Understanding the challenges and opportunities in transitioning to IVDR for pharmacogenomics can be complex. Learn more about how to overcome these challenges effectively.
Pharmacy Times
JUNE 6, 2024
Over the course of 15 years, epigenetic and transcriptional analysis of postmortem brain samples have revealed underlying molecular differences.
STAT
JUNE 5, 2024
LONDON — Finland is preparing to offer vaccines to people at risk of exposure to an avian influenza strain spreading among farmed and wild animals, health officials there said, potentially becoming the first country to take such a step as concerns about the threat the virus poses to people intensify. The vaccine campaign will be limited, with doses set to be available to groups including poultry farmers, veterinarians, scientists who study the virus, and people who work on fur farms housi
Fierce Pharma
JUNE 5, 2024
The scope of Bristol Myers Squibb’s $1.5 billion savings drive is beginning to come into focus. | Starting this month, BMS will begin the process of laying off around 863 employees in Lawrenceville, New Jersey, according to a Worker Adjustment and Retraining Notification (WARN) alert from the state. The move forms part of BMS’ campaign to shave off $1.5 billion in costs by the end of 2025, a company spokesperson said over email.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Healthcare
JUNE 5, 2024
A federal appeals court has upheld an injunction preventing the former head of Express Scripts from taking an executive role at CVS Health. | A federal appeals court has upheld an injunction preventing the former head of Express Scripts from taking an executive role at CVS Health.
Pharmacy Times
JUNE 5, 2024
For patients with a blood eosinophil count of 150 cells/µL or greater, tezepelumab had a significant reduction of approximately 37% in the rate of moderate or severe exacerbations.
STAT
JUNE 5, 2024
Ten weeks after government scientists discovered that H5N1 bird flu was sickening dairy cattle in the United States, many of the mysteries surrounding what is happening on affected farms remain just that. Widespread reluctance on the part of farmers to allow scientists — government or otherwise — onto their premises to study spread of the virus among infected cows has created a frustrating lack of understanding of the dynamics of this outbreak.
pharmaphorum
JUNE 4, 2024
ViVE conference highlights the key takeaways on artificial intelligence, cybersecurity concerns, and industry transactions. Stay updated on the latest trends and partnerships shaping these fields.
Fierce Healthcare
JUNE 7, 2024
Navajo veterans can now access in-person and virtual peer support groups thanks to a partnership between Televeda and the Navajo Nation Veterans Administration. | The support groups take the form of talking circles, deeply rooted in the traditional practices of Indigenous people. Televeda is also offering other virtual talking circles for women and LGBTQ+ individuals.
Pharmacy Times
JUNE 3, 2024
Patients with sickle cell disease with more than a 6-month delay transitioning from pediatric to adult care were about twice as likely to be hospitalized.
STAT
JUNE 5, 2024
In the midst of the Covid-19 pandemic, scientists and public health institutions made bold claims about the effectiveness of various policy responses such as closing schools and banning public gatherings. These claims shaped government responses and had enormous effects on the lives of billions of people around the world. Are those claims supported by data?
Fierce Pharma
JUNE 2, 2024
A 50% improvement on the time patients could live without disease progression would typically be considered remarkable for a new drug. AstraZeneca’s Tagrisso just delivered an 84% improvement. | A 50% improvement on the time patients could live without disease progression would typically be considered remarkable for a new drug. AstraZeneca’s Tagrisso just delivered an 84% and earned a standing ovation at ASCO 2024.
Fierce Healthcare
JUNE 3, 2024
Blue Cross and Blue Shield of Kansas City is leaving the Medicare Advantage (MA) market at the end of 2024, the insurer announced recently. | Blue Cross and Blue Shield of Kansas City is opting out of the Medicare Advantage market. The health plan said its relatively low membership and burdensome regulatory factors meant the company no longer view the market as financially viable.
Pharmacy Times
JUNE 3, 2024
Promises of sexual improvement may ensnare unsuspecting patients with potentially dangerous adverse effects from untested OTC remedies.
STAT
JUNE 5, 2024
An organization devoted to educating future doctors about conflicts of interest will now accept industry funding due to financial stress, prompting outrage from former members who argue the decision will undermine its mission. In a little-noticed move, the American Medical Student Association board recently approved an emergency resolution to accept money from drug and device makers, as well as health insurers, so long as funding does not exceed 25% of its operating budget.
Fierce Pharma
JUNE 2, 2024
On the eve of the American Society of Clinical Oncology’s annual meeting last week, a piece of news set off vigorous discussions. | After Akeso and Summit's ivonescimab beat Keytruda in a head-to-head trial in non-small cell lung cancer, analysts are trying to sort out the financial ramifications while biopharma insiders are eager to see the exact data.
Fierce Healthcare
JUNE 6, 2024
Restrictive health plan policies are increasingly relying on step therapy for cancer drugs, recent analysis from consulting firm Avalere shows. | Step therapy is embedded within prior auth requirements by health plans, potentially delaying critical access to care for cancer patients. In rare circumstances, patients must go through triple or quadruple step therapy.
pharmaphorum
JUNE 7, 2024
Explore how commercialisation is the new frontier for digital innovation in the pharmaceutical industry, with a focus on GLP-1 drugs, digital strategies, and reducing patient acquisition costs.
STAT
JUNE 6, 2024
Federal officials, medical organizations, and reproductive health advocacy groups have expressed outrage in response to STAT’s recent investigation revealing that women with sickle cell disease have felt pressured into sterilizations as recently as 2017 and 2022. Some said they knew of other contemporary instances of tubal ligations with questionable consent — in people with severe disabilities, for instance, or situations in which patients didn’t understand that the procedu
Fierce Pharma
JUNE 4, 2024
For several months, a U.S. security crackdown on biopharma firms suspected to be linked to the Chinese Communist Party (CCP) has continued to gain steam. | For several months, a U.S. security crackdown on biopharma firms suspected to be linked to the Chinese Communist Party has continued to gain steam. Now, several new names could be feeling the heat.
Pharmacy Times
JUNE 4, 2024
The panelists expressed concerns about clinical trial data and concluded that the benefits do not outweigh the risks, but the FDA does not have to follow their recommendation.
pharmaphorum
JUNE 6, 2024
Riding high from positive clinical trial results for its oral weight-loss therapy, Structure Therapeutics has filed a public offering that it hopes will raise $476 million
STAT
JUNE 4, 2024
Carbon dioxide monitors have been around for decades. But in 2020, they became, almost overnight, a hot commodity. All of a sudden, people wanted them to help assess the safety of indoor spaces — to gauge the likelihood of breathing in coronavirus-laced particles that until very recently had been in someone else’s lungs. No sensor can monitor how many infectious aerosols are swirling around us in real time.
Fierce Pharma
JUNE 3, 2024
Following fellow immunotherapy regimens by Roche and AstraZeneca, Bristol Myers Squibb’s Opdivo and Yervoy want to carve out a piece of the first-line liver cancer market, too. | Following fellow immunotherapy regimens by Roche and AstraZeneca, Bristol Myers Squibb’s Opdivo and Yervoy want to carve out a piece of the first-line liver cancer market, too.
Expert insights. Personalized for you.
149 
Let's personalize your content